Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study

Simple item page
dc.contributor.authorSingh, Deependra Vikramen_US
dc.contributor.authorAgarwal, Aniruddhaen_US
dc.contributor.authorGoyal, Anubhaven_US
dc.contributor.authorShroff, Daraiusen_US
dc.contributor.authorSingh, Jatinderen_US
dc.contributor.authorKumar, Pradeepen_US
dc.contributor.authorReddy, Raja Ramien_US
dc.contributor.authorVenkatesh, Rameshen_US
dc.contributor.authorNarnaware, Shilpien_US
dc.contributor.authorJoshi, Shrinivasen_US
dc.contributor.authorDelhi Retina Forum Study Groupen_US
dc.contributor.authorSingh, Deependra Ven_US
dc.contributor.authorNarula, Riteshen_US
dc.contributor.authorJoshi, Aishwaryaen_US
dc.contributor.authorAgarwal, Aniruddhaen_US
dc.contributor.authorGoyal, Anubhaven_US
dc.contributor.authorGupta, Charuen_US
dc.contributor.authorShroff, Daraiusen_US
dc.contributor.authorAnantharaman, Giridharen_US
dc.contributor.authorSingh, Jatinderen_US
dc.contributor.authorKumar, Pradeepen_US
dc.contributor.authorBawankule, Prashanten_US
dc.contributor.authorReddy, Raja Ramien_US
dc.contributor.authorJain, Rajiven_US
dc.contributor.authorVenkatesh, Rameshen_US
dc.contributor.authorTiwari, Ruchiren_US
dc.contributor.authorSugumar, Shalinien_US
dc.contributor.authorGupta, Shashank Raien_US
dc.contributor.authorNarnaware, Shilpien_US
dc.contributor.authorJoshi, Shrinivasen_US
dc.contributor.authorChoudhary, Somendra Pen_US
dc.date.accessioned2025-05-09T09:49:25Z
dc.date.available2025-05-09T09:49:25Z
dc.date.issued2024-12
dc.description.abstractPurpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age?related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab. Methods: This retrospective multicentric, real?world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best?corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow?up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch?over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow?up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection?free interval observed in eyes treated by pro?re?nata(PRN) protocol. Results: In total, 331 eyes received a mean of 3.55± 1.83 injections. Most frequent treatment protocol was PRN(53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24months follow?up. BCVA and CSFT improved significantly (P < 0.001) at all follow?ups. Two hundred and seventy?six(83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean “maximum injection?free interval” of 19.43± 8.82 weeks. IOI and retinal vasculitis were reported in 2.11%(7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow?up.Conclusion: This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection?free interval in eyes treated with PRN was 19weeks.en_US
dc.identifier.affiliationsRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, Indiaen_US
dc.identifier.affiliationsRetina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE); Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlandsen_US
dc.identifier.affiliationsRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, Indiaen_US
dc.identifier.affiliationsRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, Indiaen_US
dc.identifier.affiliationsRetina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, Indiaen_US
dc.identifier.affiliationsDepartment of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, Indiaen_US
dc.identifier.affiliationsRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, Indiaen_US
dc.identifier.affiliationsRetina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, Indiaen_US
dc.identifier.affiliationsRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, Indiaen_US
dc.identifier.affiliationsRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, Indiaen_US
dc.identifier.affiliationsRetina Department, Smt Kanuri Santhamma Centre for Vitreo Retinal Diseases, L V Prasad Eye Institute Banjara Hills, Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsRetina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE); Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlandsen_US
dc.identifier.affiliationsRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, Indiaen_US
dc.identifier.affiliationsRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, Indiaen_US
dc.identifier.affiliationsRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, Indiaen_US
dc.identifier.affiliationsRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, Indiaen_US
dc.identifier.affiliationsRetina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, Indiaen_US
dc.identifier.affiliationsDepartment of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, Indiaen_US
dc.identifier.affiliationsVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, Indiaen_US
dc.identifier.affiliationsRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsRetina Department, Save Sight Centre, Adarsh Nagar, Delhi, Indiaen_US
dc.identifier.affiliationsRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsRetina Department, Vitreo-retina Services, Tewari Eye Centre, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsRetina Department, Delhi Eye Care 4/17, Balraj Khanna Marg East Patel Nagar, New Delhi, Indiaen_US
dc.identifier.affiliationsVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, Indiaen_US
dc.identifier.affiliationsRetina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, Indiaen_US
dc.identifier.affiliationsRetina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, Indiaen_US
dc.identifier.citationSingh Deependra Vikram, Agarwal Aniruddha, Goyal Anubhav, Shroff Daraius, Singh Jatinder, Kumar Pradeep, Reddy Raja Rami, Venkatesh Ramesh, Narnaware Shilpi, Joshi Shrinivas, Delhi Retina Forum Study Group, Singh Deependra V, Narula Ritesh, Joshi Aishwarya, Agarwal Aniruddha, Goyal Anubhav, Gupta Charu, Shroff Daraius, Anantharaman Giridhar, Singh Jatinder, Kumar Pradeep, Bawankule Prashant, Reddy Raja Rami, Jain Rajiv, Venkatesh Ramesh, Tiwari Ruchir, Sugumar Shalini, Gupta Shashank Rai, Narnaware Shilpi, Joshi Shrinivas, Choudhary Somendra P. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. Indian Journal of Ophthalmology. 2024 Dec; 72(12): 1786-1794en_US
dc.identifier.issn0301-4738
dc.identifier.issn1998-3689
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/245110
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber12en_US
dc.relation.volume72en_US
dc.source.urihttps://doi.org/10.4103/IJO.IJO_757_24en_US
dc.subjectBrolucizumaben_US
dc.subjectneovascular AMDen_US
dc.subjectvascular endothelial growth factoren_US
dc.titleInitial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijo2024v72n12p1786.pdf
Size:
4.93 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Ophthalmology